AgomAb Therapeutics NV (AGMB)

AgomAb Therapeutics NV will go public soon, but the exact IPO date is still unknown.

Stock Price: Pending

IPO price not available yet

AgomAb Therapeutics NV Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Selling, General & Admin	-	10.13	6.1
Research & Development	-	39.31	26.31
Operating Expenses	-	49.44	32.41
Operating Income	-54.56	-48.02	-31.19
Interest Expense (Income)	-	-0.91	-0.22
Other Expense (Income)	2.32	-0.85	-18.96
Pretax Income	-56.88	-46.26	-12.01
Income Tax	-	0	-0.62
Net Income	-56.88	-46.27	-11.39
Free Cash Flow	-51.37	-47.5	-24.59
EBITDA	-	-46.86	-12.13
Depreciation & Amortization	-	0.31	0.1
EBIT	-	-47.17	-12.23

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).